

Supplemental Digital Content 2 Typical local site reaction in patient with PIDD over time

Time

15 minutes prior to end of infusion



End of infusion



8h post-infusion



24h post-infusion



Edema/induration: severe
Erythema: well defined

Edema/induration: slight
Erythema: none

Photos courtesy of the Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, Phase I clinical trial. Hizentra® US prescribing Information. PA, CSL Behring LLC.